Article
KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assurance.
Virchows Archiv : an international journal of pathology - 1 Jan 2013
Dijkstra J R, Heideman D A M, Meijer G A, Boers J E, 't Hart N A, Diebold J, Hirschmann A, Hoefler G, Winter G, Miltenberger-Miltenyi G, Pereira S V, Richman S D, Quirke P, Rouleau E L, Guinebretiere J M, Tejpar S, Biesmans B, van Krieken J H J M
Abstract excerpt
KRAS mutation testing is mandatory for patients with metastatic colorectal cancer who are eligible for treatment with an epidermal growth factor receptor targeting agent, since tumors with a mutation are not sensitive to the drug. Several methods for mutation testing are in use and the need for external quality assurance has been demonstrated. An often little addressed but important issue in external quality...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.